Sampling Research Pvt. Ltd. had conducted a research study on healthcare in India and the sides on Intellectual Property Protection under the law in the Pharmaceutical sector. This research was done by conducting thorough interviews of highly located people (ministers/ directors/ beneficiaries/ NGOs) across all strata on the healthcare system. Not surprisingly most of the respondents rated healthcare around India at an average of a dismal 4 points on a scale of 1-10 (where Just one is lowest and 15 is highest). Many aspects contribute to this sorry predicament. Those include:   Providing satisfactory healthcare needs of 1.Two billion people is not a simple task for any administration. There is a key divide between the rich as well as the poor in the country. Of late with the many private hospitals that are equipped with the best infrastructure the downtown rich get proper treatment and also facilities. But unfortunately India is usually rural than urban. The rural rich have to take a trip miles to avail these kind of facilities. Medical professionals are centered in urban areas with no administration policies to encourage medical professionals to go to rural areas. Quite a few efforts are on by quite a few state governments to force doctors to work in rural regions. In these areas there is a higher need for healthcare needs.    Lack involving education gives rise to sanitation along with hygiene problems. No reputable source of water supply and lack of infrastructure make people pretty prone to water borne health conditions. Good government hospitals are generally overburdened by the high people densities in cities and cannot often provide quality healthcare essential. AIIMS in Delhi is one such healthcare facility. In addition there is a poor pill delivery system because of which in turn medicines even when available never reach the masses. In addition to that drug companies are not spending more than enough in R&D to get the second and third generation drugs. On the list of programmes by the government that failed is the Family Setting up program due to cultural and also social issues thus building the huge population a major task for the administration.   On a good note over the years things have improved. Infant mortality has reduced, medical tourism has become more established and medicines have become additional accessible. In case of medical travel and leisure patients not only come to Of india from Asian countries but also by countries like UK the spot that the waiting period for any surgical procedure sometimes is several months. Prosperous healthcare programmes include the Polio drops/ DOT/ Immunization, the impact of which have to be measured.         The other issue studied was that surrounding patenting of drugs   There was mixed response here. Most of the respondents believed that the government should know the clauses first and should certainly not patent anything and everything as that would restrict the availability of drugs available in the market. Hence there should be enough conditions to help both the parties (the client and the manufacturer). Some respondents also were of the opinion that there was no harm in abusing patents to safeguard the people’s health. Inflow of FDI and innovation is not directly related to strong patenting at the least there is no such evidence in order to back this. It was experienced many respondents that economical development will not be affected in the event government breaks patents for the benefit of the masses, many cited China’s example. Hence the middle direction was most preferred with enough clauses so that monopolistic markets will not arise with the patent plan.     The drugs and pharmaceuticals sector has emerged as the top five sectors accounting for optimum foreign direct investment (FDI) influx. India is increasingly becoming a darling of pharma MNCs, who will be vying with each other to set up operations here. One of the main triggers because of this growth is the change in the particular country’s patent laws. Japan’s fourth biggest pharmaceutical company has massive plans for India. This company has just set up its operations in India and has witout a doubt rolled out two products on the domestic market, Aricept and Parit (becoming marketed by GlaxoSmithKline) — and both are doing “very well” according to newspaper reviews. The advent of the product evident era and a positive prospect for the pharmaceutical sector like a manufacturing hub has generated a significant increase in foreign investment in the drugs and drugs sector.   The sector features seen the maximum foreign lead investment (FDI) inflow amounting to $340m (Urs 1571.1 crore) in ‘04. Over the last Two-and-a-half decades, the Indian pharma companies have gained a firm foot-hold in the market, their share in the domestic market having increased from barely 10 per cent in early 1970s to over 80 % now. India has also blossomed as a major supplier of medication to the international markets, particularly over the past decade. A major factor in which contributed to the rapid development of the pharma industry is in which through skilful innovations in output processes, the Indian organizations could make cheap copies regarding patented drugs and sell these folks at very low prices when compared to anywhere else in the world. However, this particular favourable business environment will now undergo a change to give preference to drug MNCs because of their size and heavy R&D budgets. Even so, given the maturity and growth achieved by way of the pharma industry over the past ten years and the successes of main firms such as Runback, Dr Reddy’s Laboratories, Cipla, Nicholas Piramal, Glenmark, Wockhardt and many others globally, the Indian industry today is not unduly worried by the challenges of the new regime.   Medicines Minus Frontiers (MSF), the Nobel Prize winning humanitarian organisation, says that American native manufacturers of combination prescription drugs for treating HIV/AIDS victims have been critical in bringing down the cost a patient from $10,500 each month to just $350 per year. They have, so, revolutionised the treatment and good care of AIDS patients across the world.